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Drug Loading and Dissolution Properties of Dalcetrapib 
– Montmorillonite Nanocomposite Microparticles
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ABSTRACT
This work aims to transfer the fast dissolution performances of drug nanosuspensions into the 
solid state via a carrier particle assisted isolation method and explores the factors affecting the 
maximum achievable drug loading of the prepared nanocomposite microparticles. The solid 
composites of fast dissolving dalcetrapib (DCP) nanoparticles on larger montmorillonite (MMT) 
carrier microparticles have been prepared by an antisolvent precipitation method. The very high 
dissolution rate of the DCP nanoparticles is combined with the simple solid-liquid separation and 
drying of the MMT composite microparticles. The fast dissolution rate of DCP from the solid 
state nanocomposite microparticles was maintained up to a drug loading of 20.9%, and the 
formulation was stable for a minimum of 10 weeks in the solid state. Surface functionalisation of 
the MMT particles was not needed for a high and uniform attachment of nanoparticles. Addition 
of soluble surfactant and polymeric additives, generally used for stabilisation of 
nanosuspensions, was not required and even decreased the DCP nanoparticle attachment and 
thus limited drug loading.
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1. Introduction 
An increasing number of new active pharmaceutical ingredients (APIs) demonstrate poor and 
inconsistent bioavailability due to their low solubility and dissolution in gastrointestinal fluids, 
potentially risking API development1. The dissolution rates and thus, bioavailability of such 
APIs can be dramatically improved by increasing the surface-to-volume ratio of the API 
particles, that is by formulating them as nanoparticles (<1000 nm)23. Preparation of nanoparticles 
using comminution (e.g. wet milling4, high pressure homogenisation5), crystallisation (e.g. liquid 
antisolvent crystallisation6,7, supercritical fluid technologies8) or combinations of these 
approaches9 has been a focus of extensive research. However, isolation of the formed 
nanoparticles is still an unsolved challenge of the process.
Nanosuspensions are prone to physical instability due to the high surface energy of such 
systems, resulting in a particle size increase through Ostwald ripening10 or agglomeration11,12. In 
addition, if the nanosuspension contains a metastable polymorph or amorphous phase, 
transformation to a more stable phase might occur through a solvent mediated process13,14. The 
presence of API specific soluble additives such as surfactants and polymers generally improves 
the short term stability of nanosuspensions15,16,17. However, in most cases, conversion of the 
nanosuspension to a solid dosage formulation is required for long term stability and for patient 
convenience. During this conversion, the small particle size and phase properties must be 
maintained, as fusion16 or irreversible agglomeration18 of nanoparticles during isolation and 
drying processes would reduce the free surface area and hinder the e improved dissolution 
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properties. Extensive research has been conducted using freeze drying and spray drying 
techniques for the isolation of nanoparticles19,20,21,22. It has been found that a redispersable 
product might be obtained with the use of suitable cryoprotectants, lyoprotectants and matrix 
formers19,20. However, despite of the success of these drying processes in academia, the number 
of industrial applications are limited23,24. Freeze drying is a slow and expensive technique21, 
while technology and expertise availability may limit the use of spray drying24. As an alternative, 
several isolation strategies have been suggested, including spray granulation with carrier 
particles25, fluid bed coating and drying26,27,28, wet film casting29, nanoparticle embedment in 
polymer gels30, nanoextrusion31 and carrier particle assisted filtration of nanoparticles32,33. 
Depending on the drug properties, product requirements, technology cost and availability, one 
can select the most suitable method for isolation.
 Carrier particle assisted filtration of nanoparticles provides a simple, inexpensive and 
industrially feasible process for nanoparticle isolation. Khan et al.32 introduced the use of 
insoluble dibasic calcium phosphate as a microparticle carrier for the recovery of ibuprofen and 
glibenclamide nanoparticles from suspension. In the process, first a drug nanosuspension was 
prepared either by milling or antisolvent precipitation and stabilised with the use of soluble 
additives. Then the carrier microparticles were introduced into the nanosuspension to capture 
nanoparticles on their surfaces and form nanocomposite microparticles that could be easily 
removed by filtration. Although the improved dissolution properties of the nanoparticles were 
retained in the dried form, the method was limited by the low drug loading of the composite 
particles, being only 0.35 w/w%. As a development of this approach, we reported previously a 
one-step method for carrier particle mediated stabilization and isolation of fenofibrate, 
mefenamic acid33 and valsartan34 nanoparticles using surface functionalised montmorillonite as 
carrier microparticles in an antisolvent precipitation process. In this process, the use of soluble 
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additives was not required as the fast attachment of nanoparticles onto the montmorillonite 
surface stabilised the particles, eliminating the need for a time-consuming additive selection 
process. However, surface functionalisation of the negatively charged carrier microparticles 
using a positively charged cationic polymer, protamine sulphate salt, was necessary to improve 
drug loading of the product nanocomposite microparticles up to 33 w/w% (depending on the 
specific drug) while maintaining the enhanced dissolution rates due to the high surface area of 
the nanoparticles.
The above studies introduced the promising concept of carrier mediated nanoparticle 
isolation, combining simplicity with industrial relevance. However, how the presence of soluble 
additives and the functionalisation of the carrier particle surface affects the preparation of highly 
loaded drug–carrier nanocomposite microparticles while maintaining high dissolution rates needs 
to be explored further. The carrier particles appear to stabilise nanoparticles during the 
antisolvent precipitation process33,34 when present during or just after nucleation, without the 
need for soluble additives. In contrast, some other nanoparticle processes such as wet milling 
may still require the use of additives if the nanosuspension is not stable during the milling stage, 
prior to introducing the insoluble carrier32. Montmorillonite carrier particles had to be 
functionalized to preserve the dissolution rates at increased drug loadings for fenofibrate33 and 
valsartan34 but it is unclear whether this is necessary for all drugs or is drug specific. 
This work focuses on the filtration based carrier particle supported isolation of nanoparticles, 
and explores the factors affecting the maximum achievable drug loading of the prepared 
nanocomposite microparticles while maintaining high dissolution rates. Adding to previous 
work32,33,34, the influence of various soluble surfactant and polymeric additives on the crucial 
step of nanoparticle attachment onto the carrier microparticles is investigated, which highly 
affects the maximum achievable drug loading of the final product. The work also demonstrates 
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that the surface zeta potential of drug nanoparticles is critical to obtain a high drug loading onto 
carrier particles while maintaining high dissolution rates. While previous studies33,34 have shown 
the necessity of surface charge modification of the carrier particles for drug nanoparticles with 
zeta potentials in the range of -25 - -40 mV, this study showed that drug nanoparticles with more 
moderate zeta potentials (< ~-15 mV) do not require this additional modification. In addition, 
while in previous work nanoparticle agglomeration was found to be the reason to limit 
dissolution rates at higher drug loadings of the nanocomposites, this study showed that the 
dissolution rate can also be limited by partial recrystallization of amorphous particles during the 
drying process.
At first, the properties of the DCP nanosuspension prepared with optimised antisolvent 
process parameters are examined in the absence of the carrier montmorillonite (MMT) 
microparticles. Then, the influence of drug loading and presence of soluble surfactant and 
polymeric additives on nanoparticle attachment onto the carrier microparticles and on the 
dissolution behaviour of the fresh suspension are investigated. Finally, the dissolution and solid 
state properties of the dried nanocomposite microparticles are characterised and the influence of 
drug loading on the stability during the isolation and drying process is identified.
Dalcetrapib (DCP) is a poorly water soluble (~0.02 µg/mL35) cholesterol ester transferase 
protein inhibitor36, that was in clinical development for treating cardiovascular diseases by 
Roche until 2012. Although the original trials did not show a clinical efficacy, it has been found 
recently that the drug could potentially be beneficial for a genetic subgroup 37. To our 
knowledge, a nanoparticle formulation of the drug does not exist. 
The carrier microparticle MMT, an insoluble aluminosilicate clay, is widely used in the 
pharmaceutical industry as a traditional excipient38 and also extensively studied for use in 
modified drug delivery systems39,40,41 due to its low cost, non-toxicity and easy modifiability. 
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2. Materials and Methods
2.1. Materials 
Dalcetrapib (DCP, Form A) was kindly donated by Roche. Ethanol (>99.9) was purchased 
from Lennox. Methanol (HPLC grade) and sodium chloride (NaCl) was obtained from Fisher. 
Montmorillonite K10 (MMT,  D50=28.0±1.3 µm, determined by laser diffraction method33), 
protamine sulphate salt (PA), polyvinylpirrolidone (PVP, 40kDa) hydroxypropylmethylcellulose 
(HPMC, 15cP), Pluronic® F127 (PF127), Tween 20, sodium docusate (dioctyl sulfosuccinate 
sodium salt, DOSS), hydrochloric acid (HCl) and sodium dodecyl sulphate (SDS) was purchased 
from Sigma Aldrich. Deionised water was used for aqueous solutions (18 MΩ. Elga, purelab 
Ultra). All chemicals were used as received. The molecular structure of DCP is presented in 
Figure 1a. 
2.2. Preparation of DCP nanoparticles and DCP– MMT nanocomposite microparticles
DCP nanoparticles were prepared by an antisolvent precipitation method and isolated using 
MMT as carrier microparticles. In a general experiment, DCP solution was prepared by 
dissolving 60 mg/mL DCP in ethanol. The antisolvent was 9 mL water containing 150 – 1350 
mg MMT, equilibrated under agitation for at least 2 h prior to use. DCP nanoparticles were 
prepared by the quick injection of 1 mL DCP solution at 25.0 ˚C into the antisolvent at 5.0 ˚C 
under magnetic stirring (1000 rpm). After 1 min aging time, the particles were filtered (Whatman 
grade 1, 10 µm filter pore), washed with 5 mL water and dried under high vacuum (<27 Pa) at 
room temperature. Aging time refers to the time elapsed from the injection of drug solution into 
the antisolvent until sampling the suspension for characterisation or isolation of the particles. A 
control DCP suspension in the absence of MMT was prepared the same way; however, in this 
case, isolation of the particles was not possible. Exceptions from this procedure were made when 
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the antisolvent process parameters were optimised and the influence of soluble additives was 
studied, detailed below. 
At first, the concentration of DCP in the solvent (cDCP) and the antisolvent to solvent ratio 
(AS/S) was optimised in the absence of MMT and soluble additives by characterising the size of 
the nanoparticles in suspension at 1 min aging time (Figure S1 in Supplementary information). 
The experiments were performed at a total final suspension volume of 10 mL, varying cDCP 
between 30-120 mg/ml and using an AS/S of 9 or 19. From these experiments, the concentration 
of cDCP=60 mg/mL and AS/S=9 were selected for further studies which conditions offered a good 
solid load of the suspension (6 mg/ml suspension) at a reasonably small particle size. The short 
term stability of these particles in suspension was assessed by measuring the particle size at 
different aging times. 
When the influence of additives was studied, the amount of each additive was 2.2 mg/g 
MMT, unless otherwise specified, at a fixed amount of 225 mg MMT in each experiment. The 
additives were either present in the antisolvent for more than 2 hours prior to the injection of the 
drug solution or added to the already prepared suspension as a 1 mL concentrated additive 
solution in water at 15 s aging time. When the influence of timing of MMT addition on the 
nanoparticle attachment was investigated, MMT was added as a powder at 15 s aging time to the 
suspension of nanoparticles, and the suspension was left stirring for an additional 1 min.  
The mass of DCP nanoparticles that attached onto MMT particles was indirectly determined 
by measuring the drug content in the filtrate after filtration. While MMT particles (average size 
of 28 µm) or DCP nanoparticles that attached onto MMT are retained by a filter with a pore size 
of 10 µm, DCP nanoparticles that are not attached onto MMT can pass through. Centrifugation 
was also used to confirm that the carrier particles do not act as a filtration aid but adsorb DCP 
nanoparticles from suspension. Suspensions of DCP – MMT nanocomposite microparticles were 
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centrifuged for 1 min at 10000 rpm using a Micro Star 12 Microcentrifuge, conditions that 
enabled complete settling of MMT particles in the absence of DCP. The filtrate or supernatant 
was diluted tenfold with methanol to dissolve any DCP particles present and its concentration 
was determined using a Shimadzu UV-VIS spectrophotometer (λ=246 nm). The percentage of 
isolated DCP nanoparticles, assumed to attach onto MMT when present, and DCP loading of the 
composite, that is defined as the actual percentage of DCP nanoparticles in DCP – MMT 
nanocomposite microparticles, were calculated as the following: 
mDCP isolated (mg) = mDCP total – mDCP filtrate or supernatant (1)
isolated DCP (w/w%) = (mDCP isolated/mDCP total) x 100 (2)
DCP loading (w/w%) = (mDCP isolated / (mDCP isolated + mMMT)) x 100 (3) 
2.3. Characterisation of DCP nanosuspensions in the absence of MMT
The size of DCP particles in suspension in the absence of MMT was characterised by a 
Malvern Zetasizer Nano ZSP, utilizing a dynamic light scattering technique. At a certain aging 
time, suspensions were diluted 80 times with water at 5 ˚C, filled into a disposable cuvette, and 
the temperature was further equilibrated for 120 s at 5 ˚C prior the measurement. Each sample 
was measured with three consecutive sub-runs at a scattering angle of 173°.
The zeta potential of DCP nanosuspensions in the absence of MMT was determined by a 
Malvern Zetasizer Nano ZSP, using a folded capillary cell (cell type: DTS1070). The 
nanosuspension was sampled at 1 min aging time and diluted 20 times using a filtrate of the 
same formulation (filtered with a 0.2 µm pore sized nylon syringe filter). The temperature was 
equilibrated for 120 s at 5 ˚C prior to the measurement. Each sample was measured with three 
consecutive sub-runs. The zeta potential was calculated using the Henry equation with 
Smoluchowski approximation. 
Page 8 of 40
ACS Paragon Plus Environment






























































Three separate samples were prepared and analysed for each measurement. 
2.4. Characterisation of dried DCP – MMT nanocomposite microparticles, DCP – MMT 
physical mixtures and as received DCP
The polymorphic form was determined using a Philips PANAlytical X’pert diffractometer. 
The sample was placed between amorphous tapes and measured in transmission geometry using 
Ni filtered Cu Kα radiation (λ=1.54 Å), 40 kV accelerating voltage and 40 mA anode current. 
The diffraction pattern was collected between 5˚ and 30˚ (2θ).
Thermal analysis was performed using a Perkin-Elmer Pyris1 differential scanning 
calorimeter. Powder containing approximately 1 mg DCP was placed into a closed 
aluminum pan, and the sample was characterized from 15 °C to 95 °C using 30 mL/min 
N2 gas flow and 50 °C/min heating rate. As a control, amorphous DCP was also 
prepared by cooling the pure melt at a rate of 50 °C/min from 95 °C to 15 °C and 
characterized at a second reheat of the sample. Calibration was made using indium and 
the same heating rate. A minimum of five individually prepared samples were 
characterized to determine the onset temperature and enthalpy of melting. Enthalpy of 
melting is reported with respect to the amount of DCP in the physical mixture or in the 
nanocomposite microparticles.
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The particle size distribution of as received DCP crystals was determined using a Malvern 
Morphology G3 in dry mode. A portion of particles was taken out from the bulk after appropriate 
sample homogenisation. Particles were dispersed on a glass slide using an SUP dispersion unit 
and 1 bar pressure, and the length and width of 50000 needle-like crystals were measured at a 
magnification of 2.5 to obtain a representative number based distribution. D50length and D50width 
are reported as the length and width at which 50% of the crystals are shorter/thinner. 
The size and surface architecture of MMT and DCP-MMT composite particles were studied by a 
HITACHI SU-70 scanning electron microscope (SEM) at 3 kV. To prepare the samples, a small 
amount of isolated particle was placed onto an adhesive carbon tape attached to a cylindrical 
aluminum sample holder and gold sputtered at 20 mA for 1 minute using an EMITECH K550. 
2.5. Dissolution studies
The solubility of the as received, stable Form A DCP in dissolution media consisting of 0.1 M 
HCl, 2 g/L NaCl and 2.5 g/L SDS was determined by saturating the solution at 37.0 °C. An 
excess of solid was added to a stirred solution and equilibrated for 24 h. After 24 hour settling of 
the solid phase, the supernatant was filtered using a nylon syringe filter (0.2 µm pore size, 
VWR), discarding the first 3 mL to avoid possible adsorption of the DCP molecules to the filter 
membrane. The filtrate was diluted with the dissolution media fivefold, and the concentration of 
DCP was determined using a Shimadzu UV-VIS spectrophotometer (λ=244 nm). 
The dissolution of fresh (not isolated) DCP nanosuspensions and different (freshly prepared 
or isolated to dryness) DCP – MMT formulations was measured by adding an equivalent of 12.5 
mg DCP of each sample into 500 mL dissolution media at 37 °C to maintain sink conditions 
(solubility: 153.2±0.2 µg/mL) and stirring with a magnetic stirrer bar (300 rpm). At specific 
intervals, a 3 mL aliquot was withdrawn and filtered through a nylon syringe filter (0.2 µm pore 
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size, VWR) discarding the first 2 mL of the filtrate and analysed by the above mentioned UV-
VIS method without dilution. While only the first 15 min of the dissolution experiments are 
shown in the manuscript for presentation purposes, all samples reached complete dissolution. 
Suspension samples reached 100±5%, whereas all solid samples reached 100±7% dissolution 
during the experiments, with the highest error being at low DCP loadings. In the cases of 
suspensions, the deviation from 100% is likely due to the sampling from unstable suspensions, as 
the relatively large DCP – MMT nanocomposite microparticles settled quickly when the stirring 
was stopped. In the cases of solid samples, a lower water content of the processed MMT 
compared to the unprocessed MMT contributes to the deviation. Thus, for a more accurate 
comparison of the formulations, all dissolution results were normalized to 100%. Dissolution 
tests were carried out in triplicate (in the absence of additives), or in duplicate (in the presence of 
additives). 
3. Results 
3.1. Nanoparticle formation in the absence of carrier particles
As a first step for the preparation of DCP – MMT nanocomposite microparticles, antisolvent 
precipitation process conditions were optimised in the absence of MMT in order to achieve a 
good yield at a reasonably small particle size. From this work AS/S=9 and the DCP 
concentration of 60 mg/mL selected (Figure S1, supplementary information). The injection of 
DCP solution into water during the antisolvent precipitation process resulted in the immediate 
precipitation of the drug, forming a white suspension. Figure 1b presents the particle size 
distribution of the formed DCP nanoparticles at 1 min aging time, prepared with the optimised 
process conditions. The average size of these particles was 429±51 nm, while their zeta potential 
was -14.0±2.5 mV. 
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Figure 1 (a) Molecular structure of DCP and (b) particle size distribution of DCP particles at 1 
min. 
By increasing aging time, the size of the particles first increased from 429 nm to 693 nm 
within the first 7 min then gradually decreased to 403 nm by 20 min (Figure S2, supplementary 
information). However, after 3 min, large, visually detectable agglomerates also appeared in the 
suspension, indicating instability. Since these agglomerates settled quickly after sampling, only 
the size of small particles coexisting with these large agglomerates (not measurable) were 
detected by DLS technique at later aging times (>3 min). While stability could be improved in 
the presence of soluble additives as found in several other API systems4,17, the duration of 
stability is not critical for nanoparticle isolation with MMT as shown later. 
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In the absence of MMT, attempts were made to isolate the nanoparticles at 1 min aging time; 
however, none of the traditional methods were successful. The nanoparticles blocked the 0.2 µm 
pore sized filter membrane, and were highly unstable during evaporation drying of a droplet of 
suspension (at 50 °C or under vacuum (<27 Pa) at room temperature) or freeze drying, forming 
large crystals. Thus, while formation of the nanoparticles was easy to address using an 
antisolvent precipitation process due to the high supersaturations generated42,43, nanoparticle 
stabilisation in suspension and during isolation was the key challenge to be tackled. 
3.2. Nanoparticle attachment onto carrier particles
 When present initially in the antisolvent, MMT was highly efficient as a carrier system for 
capturing DCP nanoparticles. Table 1 reports the actual loading of DCP nanoparticles in the 
formed DCP – MMT nanocomposite microparticles, depending on the amount of MMT present 
in the system. The results show that more than 99% of the total amount of DCP (60 mg) was 
retained even with 150 mg of MMT, corresponding to 28.4% drug loading in the composite. In 
contrast, in the absence of MMT, 75.6% of DCP passed through the filter paper, resulting in a 
milky filtrate containing the nanoparticles. The fact that nanoparticles were attaching onto MMT 
from suspension was also verified by analysing the supernatant of the corresponding suspensions 
after centrifugation, revealing that 97% of the total amount of DCP did attach to the MMT up to 
28.4% composite loading. In contrast, only 56.1% of the particles separated into the bottom 
sediment under the same conditions in the absence of MMT.
Table 1 Percentage (w/w) of DCP recovered by filtration or by centrifugation at 60 mg DCP and 
different amount of MMT in the antisolvent – solvent mixture (AS – S), and corresponding DCP 
loadings in DCP – MMT nanocomposite microparticles (w/w%)
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Amount of DCP 
in AS-S, mg
Amount of MMT 
in AS-S, mg
DCP isolated by 
filtration, w/w%
DCP isolated by 
centrifugation, w/w%
DCP loading in 
DCP-MMT*, %
60 1350 99.8±0.2 99.8±0.03 4.2
60 450 99.7±0.2 99.0±0.1 11.7
60 225 99.2±0.6 97.7±0.2 20.9
60 190 99.3±0.6 97.6±0.02 23.9
60 150 99.3±0.3 97.2±0.3 28.4
60 100 98.8±0.7 95.4±0.3 37.2
60 Control (no MMT) 24.4±1.6 56.1±3.2 -
* Calculated based on DCP isolation by filtration
Figure 2 shows the influence of soluble surfactant (DOSS, Tween 20) and polymeric (HPMC, 
PVP, PF127, PA) additives on nanoparticle attachment to MMT. High attachment of DCP 
nanoparticles onto MMT was maintained in the presence of Tween 20, PVP, PF127 and PA as 
single additives, shown by the high percentage of isolated particles both by filtration and 
centrifugation. In contrast, the presence of DOSS as a single additive, and in combination with 
HPMC and with PVP greatly reduced the attachment to MMT resulting in only 10.1%, 28.1% 
and 6.7% of the mass of DCP, respectively, separating to the bottom sediment during 
centrifugation. These values being lower than that of the control suspension (56.1%) indicate that 
not just particle attachment but also the size of the particles is decreased in the presence of these 
additives, and these smaller particles would need more time to settle. Interestingly, using 
filtration instead of centrifugation, a higher amount of DCP was isolated with MMT when DOSS 
or combination of DOSS with HPMC is used. This was accompanied by a slower filtration time 
of approximately 3 min and 2 min, respectively, as compared to less than 1 min in the presence 
of MMT only. In contrast, the combination of DOSS with PVP in the presence of MMT allowed 
for the nanoparticles to pass through the filter paper, similarly to the control nanosuspension. 
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When the combination of DOSS with HPMC or PVP was added to the suspension 15 s after 
the injection of the drug solution into the antisolvent containing MMT, high percentage of the 
particles could be isolated both with filtration (>98.7%) and centrifugation (>91.5%) showing 
that the process of nanoparticle attachment to MMT is fast and non-reversible.
When MMT was added at 15 s aging time to the nanosuspension prepared in the absence of 
additives, the amount of particles that could be isolated both by filtration or centrifugation only 
reduced by 3% compared to that when MMT was present initially in the antisolvent. In contrast, 
later addition of MMT to a nanosuspension prepared in the presence of Tween 20, PVP or PF127 
resulted in the isolation of only 19.4 – 66.6% DCP by centrifugation, as opposed to the isolation 
of more than 97.5% DCP when both MMT and the additives were present initially. 
Figure 2 Influence of different additives on the isolation of DCP nanoparticles with MMT 
particles. Additives added at 2.2 mg/g MMT. Isolation by centrifugation (blue bars) or filtration 
(red bars). 100% isolation corresponds to a drug loading of 21.1% on MMT. When indicated, 
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additives were injected as 1 ml concentrated solutions or MMT added as a powder at 15 s aging 
time.
3.3. Dissolution profiles of drug – carrier nanocomposite microparticles in suspension
In the absence of MMT, the dissolution of the free nanoparticles from a freshly prepared 
suspension (not isolated) was very fast due to the large surface area of DCP nanoparticles, being 
complete within 2.2 min (Figure 3). Dissolution of DCP nanoparticles attached onto MMT (from 
fresh suspension, not isolated) was somewhat slower and the dissolution rate decreased with 
increasing nanoparticle loading of the composite up to 20.9% DCP. Further increase of the 
loading to 23.9% and to 28.4% did not have a significant effect on the dissolution profile. Within 
15 min, all samples reached 100% dissolution.
Figure 3 Dissolution behaviour of DCP nanoparticles free in suspension (not isolated) and 
attached onto MMT in suspension (not isolated) at different DCP loadings of the product 
nanocomposite microparticles.
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The presence of PA or PVP at an amount of 2.2 mg/g MMT, which did not interfere with the 
high level of nanoparticle attachment, did not show any improvement on the dissolution profile 
of the freshly prepared suspension at 20.9% drug loading of the nanocomposite microparticles, 
Figure 4. In addition, in the case of the positively charged surface modifier PA, required for the 
isolation of negatively charged fenofibrate and mefenamic acid nanoparticles33, no significant 
improvement was found even at a decreased DCP nanoparticle loading of 4.2% or increased 
amount of PA up to 22 mg/g MMT (Figure S3a and S3b in supplementary information, 
respectively). Dissolution of DCP nanoparticles from a freshly prepared suspension (not isolated) 
in the presence of MMT was faster with DOSS or with the combination of DOSS and PVP 
compared to the dissolution profile  in the presence of MMT only (Figure 4). However, in these 
cases, the dissolution rate improvement was associated with the presence of free nanoparticles in 
suspension, not attached onto MMT, as only a small amount of DCP particles could be isolated 
by centrifugation in the presence of DOSS or combination of DOSS and PVP (Figure 2, poor 
isolation efficiency). Thus the dissolution rate improvement with these additives cannot be 
transferred to an increased dissolution rate in the dried state. 
From these results, it is clear that the presence of those soluble additives which maintain high 
nanoparticle attachment to MMT and thus, high isolation efficiency, cannot improve the 
dissolution rate of DCP nanoparticles any further.
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Figure 4 Dissolution profiles of fresh DCP suspension (not isolated) and fresh suspensions of 
DCP – MMT composites (not isolated) prepared in the presence of selected additives, each at 2.2 
mg/g MMT. The ratio of DCP to MMT was equal in all the suspensions, corresponding to a 
21.1% DCP loading in DCP – MMT nanocomposites microparticles when 100% is attached. 
Overlapping dissolution curves: DCP with MMT + DOSS and DCP with MMT + DOSS + PVP; 
DCP with MMT and DCP with MMT + PVP and DCP with MMT + PA.
3.4. Dissolution profiles of isolated and dried drug – carrier particle composites
DCP – MMT nanocomposite microparticles, free from additional soluble additives, were 
prepared by an antisolvent precipitation method and isolated using a simple and fast filtration 
process with an industrially relevant filter pore size (10 µm). Upon addition to the dissolution 
media, up to DCP loadings of the product composite as high as 20.9%, the dried sample quickly 
redispersed forming a suspension of composite particles. DCP dissolution from the composites 
was fast, reproducible and comparable, reaching 80% within the first 5 min and 90% within 15 
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min (Figure 5). Further increase of the loading to 23.9% resulted in a slightly slower dissolution, 
reaching 86.8% within 15 min. However, with increasing the loading to 28.4% the dissolution 
became more variable and slower. The dissolution of the isolated DCP-MMT composite particles 
is also compared with the dissolution of micron-sized as received DCP crystals, Figure 5. DCP 
dissolution from the composites was superior to the dissolution of the as received DCP crystals 
(D50length=12.3 µm and D50width =6.23 µm, size data in Figure S4 in supplementary information), 
the latter only reaching 11.7% in the first 15 min.
Figure 5 Dissolution of isolated and dried DCP – MMT composites at different DCP loadings 
and that of the as received DCP crystals.
The improved dissolution of the particles from 20.9% DCP – MMT nanocomposite 
microparticles remained unchanged after 10 weeks of storage at room conditions, suggesting 
reasonable stability in the solid state. (Figure S5, Supplementary information).
Page 19 of 40
ACS Paragon Plus Environment






























































Comparing the dissolution profiles of DCP – MMT composites in fresh suspensions with 
those of the dried formulations (Figure S6, supplementary information), at first the dissolution 
rate is essentially the same at a given drug loading of the composite. However, after the initial 
period, the dissolution of the dried sample became slower regardless of loading. While the 
difference in the percentage of dissolved DCP from the fresh suspensions and dried samples was 
similar and less than 10% at 15 min for 4.2% and 20.9% DCP loadings, it was more than 30% at 
28.4% DCP loading, indicating a higher instability of this sample during isolation and drying. 
Attempts were made to determine the surface architecture of DCP-MMT composite particles 
using SEM (Figure 6). Analyses of bare MMT (Figure 6a) revealed that the carrier is composed 
of  larger micron sized particles with a portion of smaller particles attached onto the surface of 
the large ones (D50=28.0±1.3 µm, determined by laser diffraction method33), creating an uneven 
surface and also implying the presence of voids on the bare MMT structure. On the surface of the 
composites, Figure 6b, SEM analyses fails to distinguish between DCP and MMT particles. 
Figure 6. Scanning electron micrographs of bare MMT (a) and DCP – MMT (b) particles
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3.5. Crystal structure and crystallinity
To understand the difference in the dissolution profiles of the fresh suspensions and dried 
formulations, the crystallinity of isolated DCP particles at a composite loading of 20.9%, 23.9% 
and 28.4% was characterised using PXRD. The PXRD profile of dried DCP – MMT 
nanocomposite microparticles along with that of the as received DCP and physical mixtures of as 
received DCP with MMT are presented in Figure 7. As received DCP was in the stable 
polymorphic form, Form A44,45, with characteristic peaks at 8.0°, 17.1°, 18.6°, whereas MMT has 
a strong peak at 26.7°. In the physical mixtures, all the diffraction peaks of DCP were clearly 
visible with unchanged positions beside the peaks of MMT. The characteristic peaks of Form A 
DCP were also present in the diffractograms of the composite particles, however, the intensity 
ratios of DCP and MMT peaks were significantly reduced compared to those of the 
corresponding physical mixture with the same DCP – MMT ratio, indicating a high amount of 
amorphous DCP content. In addition, the intensity ratios of the different DCP peaks (e.g. the 
ratio of the Form A peaks at 8.0° and at 18.6°) were also altered revealing altered morphology of 
the crystalline parts. 
In theory, the area (or intensity) ratio of a peak corresponding to DCP and a peak 
corresponding to MMT should be proportional to the changing weight ratio of DCP to MMT in 
the composite samples, if the percentage of DCP that is in crystalline state is unchanged.  By 
plotting the area ratio of the DCP peak at 8.0° and that of the MMT peak at 26.7° versus 
DCP/MMT weight ratios in the composite samples (Figure S7 in supplementary information), a 
positive deviation from linearity was found suggesting an increasing percentage of crystalline 
DCP content with increasing DCP loading from 20.9% and 23.9% to 28.4%. 
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Figure 7 PXRD profiles of DCP – MMT composites: (a) 20.9% DCP with MMT, (b) 23.9% 
DCP with MMT, (c) 28.4% DCP with MMT; physical mixtures of as received DCP and MMT: 
(d) 20.9% DCP with MMT, (e) 23.9% DCP with MMT, (f) 28.4% DCP with MMT; (g) pure as 
received DCP; (h) MMT; (i) background. Intensity of the pure DCP profile has been reduced by 
a factor of 5 for presentation purposes.
The crystallinity of isolated DCP nanoparticles was also studied by DSC (Figure 8), 
determining the enthalpy of fusion, ΔHf, summarised in Table 2. The onset of melting of pure 
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DCP was 67.9±0.8 °C at a heating rate of 50 °C/min and the enthalpy of melting was 
ΔHf=84.6±2.1 J/g (Figure 8, g). Within the temperature range that was selected to monitor the 
thermal behaviour of DCP, the DSC curve of MMT does not show any thermal events (Figure 8, 
i), as MMT would have a much higher melting point (>1000 °C). The percentage of crystalline 
content of DCP attached onto MMT may be calculated by the ratio of enthalpy of fusion of the 
samples and that of a 100% crystalline reference if no recrystallization of the amorphous phase 
takes place during heating, and the onset of melting and the enthalpy of fusion of the crystalline 
DCP is not altered in the presence of MMT46. The absence of a melting endotherm of a reheated 
100% DCP sample after fast cooling of the melt verifies that the amorphous form does not 
recrystallize at the applied heating rate (Figure 8, h). The melting onset temperature of DCP 
physically mixed with MMT (Figure 8, d-f) and DCP – MMT nanocomposite microparticles 
(Figure 8, a-c) only decreased marginally, by a maximum of 1.5 °C. However, the enthalpy of 
fusion of the physical mixtures, normalized to the mass of drug present, reduced to 54.1% - 
68.1% compared to the pure drug, originating from an interaction between the melted DCP 
molecules and MMT47. The interaction releases heat which partially compensates the energy 
needed for breaking up molecular interactions in the DCP crystal lattice during melting 
(endothermic event). This can be seen by the decreased apparent heat of fusion of DCP in the 
physical mixtures in comparison to the pure DCP. Thus, crystalline content in DCP – MMT 
nanocomposite microparticles were estimated using the heat of fusion of the corresponding 
physical mixtures. Important to note, that this method may overestimate crystalline content if, 
due to spatial arrangement of the crystalline and amorphous DCP particles around MMT, the 
percentage of molecules interacting with MMT during melting is less than those in the 
corresponding physical mixtures. With the above mentioned assumption, the crystalline DCP 
content of the samples at 20.9%, 23.9% and 28.4% drug loadings were estimated to be 9.2±7.2%, 
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17.9±3.9% and 38.9±11.3%, respectively (Table 2). These values correlate with the amount of 
undissolved DCP at 15 min, suggesting that the decrease of the dissolution rate above 20.9% 
DCP loading is governed by an increase of DCP crystallinity.
Figure 8 DSC curves showing melting peak of DCP from (a-c) DCP – MMT composites having 
a DCP content of (a) 20.9%, (b) 23.9%, (c) 28.4%; (d-f) physical mixtures of DCP and MMT at 
a DCP content of (d) 20.9%, (e) 23.9%, (f) 28.4%; (g) pure DCP; (h) pure DCP at second 
heating; and (i) DSC curve of MMT. 
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Table 2 Heat of fusion (ΔHf) of DCP, on MMT at different loadings (“Sample”) and that of 
physical mixtures of Form A DCP and MMT. ΔHf of pure Form A DCP is also included. 100% 









DCP undissolved after 
15 min, %
20.9% 4.0±2.9 43.5±2.6 9.2±7.2 9.3±2.2
23.9% 9.5±1.4 53.2±3.7 17.9±3.9 13.2±1.6
28.4% 22.4±5.1 57.6±3.6 38.9±11.3 32.8±8.5
100% - 84.6±2.1 - 89.9±0.1
4. Discussion
DCP is a highly hydrophobic drug due to its large hydrocarbon content (Figure 1a). Due to 
this high hydrophobicity and the only moderate negative zeta potential of the particles in 
suspension, -14.0±2.5 mV, the nanosuspension is highly unstable. Within a few minutes in the 
absence of MMT carrier particles or soluble additives, particle growth commences (Figure S2, 
Supplementary information). By addition of MMT carrier particles, a nanocomposite 
microparticle is formed, where the fast dissolution rate is maintained, even after isolation and 
drying. Thus this simple process combines the advantages of nanoparticle stabilization with a 
filtration based isolation technique. 
The aluminosilicate MMT has an expandable layered structure where an octahedral sheet is 
sandwiched between two tetrahedral sheets48. Isomorphous substitution of Si4+ with Al3+ in the 
outer siloxane sheet introduces negative charge and hydrophilic patches onto the originally 
hydrophobic surface49. MMT, when present initially in the antisolvent or added 15 s after the 
injection of drug solution (Table 1 and Figure 2), provides a surface for DCP nanoparticle 
attachment through hydrophobic interaction between the large hydrocarbon groups of DCP and 
the hydrophobic siloxane patches49,50,51. In addition, interaction of DCP with the MMT surface 
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through hydrogen bonding is also possible. A favorable interaction between DCP molecules and 
MMT was also verified by a reduced heat of fusion in the physical mixtures (Table 2). Although 
the surface of MMT particles bears a significant negative charge (zeta potential: -26.9±1.2 
mV33), surface functionalisation with the positively charged protamine was not required to 
achieve high drug loadings at a maintained fast dissolution rate (Figure 4 and Figure S3 in 
Supplementary information). This can be explained by the less negative charge of DCP 
nanoparticles compared to that of the previously studied fenofibrate (-25.3±0.9 mV33) 
mefenamic acid (-35.3±1.3 mV52) or valsartan (-42.5±1.4 mV34) nanoparticles. 
While it is hypothesized that DCP nanoparticles adsorb to the MMT surface mainly through 
hydrophobic interactions, a better understanding of the architecture of the DCP – MMT 
nanocomposites still needs to be elucidated. Unfortunately SEM analysis, Figure 6, fails to 
distinguish between API and MMT particles on the surface due to the roughness of the surface of 
the MMT particles and the immature crystal formation of the API.
Several applications has been described utilizing MMT as an absorber in waste treatment48, 
drug delivery and extended release formulations39,40,41, where ions/molecules are absorbed in the 
expandable layers of MMT. In our application, however, we rule out the significance of 
molecular DCP absorption based on the following findings. DCP nanoparticles quickly formed 
when added to the aqueous phase containing MMT and could be isolated with >99% efficiency 
within one minute. This isolation efficiency remained the same when MMT was added to the 
system after precipitation, verifying that interaction occurs with DCP nanoparticles on the outer 
surface and not with molecular DCP. In addition, dissolution of DCP was fast (90% within 15 
min) and complete (reaching 100%) from the composite particles. These data contrasts with 
extended release formulations where release of adsorbed molecules is observed over several 
hours41. From SEM images of bare MMT (Figure 6a), there are spaces in the uneven surface of 
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the MMT and between particles on the surface where nanoparticles could become trapped. 
However, any significant occlusion of the nanoparticles from the bulk dissolution media would 
slow the subsequent dissolution of the DCP from the nanocomposite, which was not observed.
A selection of soluble additives was studied to cover a wide range of molecular structures and 
thus interaction abilities that could be categorised as the followings: non-ionic polymer with 
hydrogen bonding ability (HPMC), non-ionic polymer with no hydrogen bonding ability (PVP), 
non-ionic block-copolymer (PF127), cationic polymer (PA), non-ionic surfactant (Tween 20), 
anionic surfactant (DOSS). While the presence of most of the studied additives (Tween 20, PVP, 
PF127, PA) did not interfere with the high isolation efficiency using MMT, determined both by 
filtration and centrifugation, attachment to MMT was greatly reduced in the presence of an 
anionic surfactant DOSS alone or in combination with HPMC or PVP (Figure 2). Adsorption of 
DOSS ions onto the surface of DCP not only decreases surface hydrophobicity like the 
adsorption of other uncharged surface active stabilisers15 but is also expected to increase the 
negative surface charge of DCP nanoparticles. This in turn increases electrostatic repulsion 
between DCP nanoparticles and the negative patches of the MMT surface or already attached 
DCP nanoparticles. Adsorption of DOSS onto the bare MMT surface might also contribute to an 
increased electrostatic repulsion. Attachment was also reduced when MMT was added 15 s after 
nanoparticle precipitation in the presence of Tween 20, PVP or PF127, showing that DCP 
nanoparticles already coated with stabilisers have a lower affinity for interaction with MMT 
probably due to a lower hydrophobicity of the nanoparticle surface or steric stabilization12. These 
results highlight that the carrier, added to the system prior to or just after the nucleation of the 
nanoparticles, could attract drug nanoparticles more efficiently when other soluble stabiliser 
additives are omitted. Thus, the integration of carrier mediated nanoparticle isolation at an early 
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stage of the formulation development process can eliminate the need for selection of soluble 
additives for stabilization. 
Even directly from the fresh suspension and at low drug loading, DCP loaded nanocomposites 
have a slightly lower dissolution rate compared to that of the free nanoparticles (Figure 3). The 
initial dissolution rate over the first 40 seconds has decreased by 30% at 4.2% drug loading 
(Table 3), and further decreases occur up to 20.9% drug loading. In these experiments the 
loading is increased by decreasing the amount of MMT, while the amount of DCP remains 
constant. Accordingly, the reduced dissolution rate is related to the fact that the full surface area 
of the nanoparticles is not exposed to dissolution, because part of the area is attaching to the 
MMT surface, and possibly part of the nanoparticles are covered by other DCP particles. This 
latter becomes more prominent as the DCP loading of the composite increases, further reducing 
the surface area per unit mass of DCP exposed to dissolution, and thus, the dissolution rate. 
Above 20,9% loading, however, further decrease in the initial dissolution rate could not be seen, 
suggesting e.g. a looser attachment of DCP nanoparticles in the outer layers and/or an actual 
release of nanoparticles from the surface during the dissolution.
Table 3 Initial dissolution rates in fresh suspensions at a given drug loading of the DCP – MMT 
nanocomposite microparticles. 
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The relatively moderate decrease of the dissolution rate with increasing loading of the 
nanocomposite microparticles contrasts with previous work33, where at higher loadings 
agglomerated patches of nanoparticles was suggested to be a reason for a more dramatic decrease 
in dissolution rate. 
The isolation and drying of the composite particles do not alter the initial dissolution rate, but 
certainly increase the time needed for complete dissolution (Figure 3 and Figure 5, compared on 
Figure S6 in supplementary information). The effect is moderate at low loading but increases at 
drug loading above 20.9%. This behaviour was found to correlate with increasing crystallinity of 
the dried DCP particles (Table 2). Accordingly, it is assumed that amorphous nanoparticles form 
initially in the suspension at all drug loadings, and may completely dissolve from the fresh 
suspensions (sampled at 1 min) within 15 min. However, after the crystalline form has nucleated 
the crystals grow at the expense of the amorphous material via a solvent mediated transformation 
in the suspension or in the wet filter cake14. In the system here, this occurs predominantly during 
the isolation and drying processes (started at 1 min aging time) and leads to a gradually 
increasing crystalline content. Remaining amorphous material will provide the initial rapid 
dissolution while the crystalline content having lower solubility and potentially increased size, 
will have a lower dissolution rate. More crystalline particles are formed at higher loadings in the 
range of 20.9 – 28.4% drug loading, possibly due to a higher local density of amorphous 
particles. Besides increasing crystallinity, particle aggregation may also contribute to the 
decreasing dissolution rates at higher loadings. Once the particles were dried, the crystalline 
content of the formulation did not change during the studied time period, as shown by their 
unchanged dissolution profile after 10 weeks storage (Figure S5 in Supplementary information). 
When the target particle size distribution of the process is in the nano size with a goal of 
increasing dissolution rates, stabilisation of the nanoparticles and separation is inherently 
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challenging. API-MMT nanocomposites reported in this study have been shown to be stable over 
10 weeks, can be applied as a technology to a range of APIs and can be produced by simple 
precipitation and filtration methods. Depending on the applied API33,34, the composite particles 
have a maximum API loading above which dissolution rate of the API is compromised, herein 
being around 20%. Thus, with even further excipients in the final dosage form, the API-MMT 
nanocomposites proposed here may only be suitable for more potent API molecules. MMT is an 
FDA approved excipient and has been reported to be good disintegrating agents53 when used 
appropriately and a lot more excipients may not be required for tableting. Alternatively a capsule 
formulation with the API-MMT nanocomposites could also be designed. These further 
downstream formulation stages are not the focus of the study here but do need to be explored to 
bring this technology to a higher technology readiness level. 
5. Conclusion
Fast dissolving drug (dalcetrapib) – carrier (montmorillonite) nanocomposite microparticles 
free from soluble additives, were prepared with an antisolvent precipitation method and isolated 
by a simple, fast, industrially relevant filtration process. In the absence of MMT carrier particles, 
DCP nanoparticles (429 nm) formed in suspension but were highly unstable and difficult to 
isolate. MMT carrier particles, when present during or shortly after nanoparticle formation, 
provided a surface for attachment of the nanoparticles, retaining more than 99% of them up to a 
corresponding DCP loading of 28.4% in the nanocomposite microparticles. Fast dissolution of 
isolated DCP nanoparticles, being far superior to that of the larger as received drug crystals, 
could be maintained even at a drug loading of 20.9% of the composite, with the formulation in 
dry state being stable for a minimum of 10 weeks of storage. The optimum drug loading was 
found to be controlled by the interplay of nanoparticle attachment efficiency, drug loading, 
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dissolution rate of attached nanoparticles and stability during isolation and drying. The use of 
soluble stabilisers was not required or even decreased nanoparticle attachment, especially when 
MMT was introduced later to a suspension of stabiliser coated nanoparticles. The MMT surface 
did not require a surface functionalisation for a uniform nanoparticle attachment and 
consequently, high dissolution rates, due to a fairly low negative charge of DCP nanoparticles 
and thus, lack of strong electrostatic repulsion with the negative MMT surface. Thus, this 
montmorillonite based carrier mediated system can enable solution crystallisation methods for 
the development of solid dose nanoparticle formulations with high drug content of dalcetrapib, 
preserving high dissolution rates and having favorable filtration properties.
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suspensions and dried samples at different DCP loadings (Figure S6), change of PXRD peak 
ratios of composite samples with increasing DCP loading (S7).
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